172 related articles for article (PubMed ID: 29695613)
1. Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity.
Solanki M; Pointon A; Jones B; Herbert K
Drug Metab Dispos; 2018 Aug; 46(8):1053-1065. PubMed ID: 29695613
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.
Xu M; Ju W; Hao H; Wang G; Li P
Drug Metab Rev; 2013 Aug; 45(3):311-52. PubMed ID: 23865864
[TBL] [Abstract][Full Text] [Related]
3. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors.
Leow JWH; Verma RK; Lim ABH; Fan H; Chan ECY
Eur J Pharm Sci; 2021 Sep; 164():105889. PubMed ID: 34044117
[TBL] [Abstract][Full Text] [Related]
4. Arachidonic Acid Metabolism by Human Cardiovascular CYP2J2 Is Modulated by Doxorubicin.
Arnold WR; Baylon JL; Tajkhorshid E; Das A
Biochemistry; 2017 Dec; 56(51):6700-6712. PubMed ID: 29200270
[TBL] [Abstract][Full Text] [Related]
5. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.
Evangelista EA; Kaspera R; Mokadam NA; Jones JP; Totah RA
Drug Metab Dispos; 2013 Dec; 41(12):2087-94. PubMed ID: 24021950
[TBL] [Abstract][Full Text] [Related]
6. [Research progress of human cytochrome P450 2J2 and its ligands].
Ma HY; Ning J; Ge GB; Yang L; Hao DC
Yao Xue Xue Bao; 2017 Jan; 52(1):26-33. PubMed ID: 29911373
[TBL] [Abstract][Full Text] [Related]
7. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes.
Leow JWH; Gu Y; Chan ECY
Eur J Pharm Sci; 2023 Aug; 187():106475. PubMed ID: 37225005
[TBL] [Abstract][Full Text] [Related]
8. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.
Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X
Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225
[TBL] [Abstract][Full Text] [Related]
9. CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity.
Evangelista EA; Lemaitre RN; Sotoodehnia N; Gharib SA; Totah RA
Drug Metab Dispos; 2018 Apr; 46(4):380-386. PubMed ID: 29343610
[TBL] [Abstract][Full Text] [Related]
10. Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy.
Karkhanis A; Hong Y; Chan ECY
Biochem Pharmacol; 2017 Jul; 135():12-21. PubMed ID: 28237650
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Ren S; Zeng J; Mei Y; Zhang JZ; Yan SF; Fei J; Chen L
Drug Metab Dispos; 2013 Jan; 41(1):60-71. PubMed ID: 23033255
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib.
Wang Z; Yong Chan EC
Drug Metab Dispos; 2022 Oct; 50(10):1332-1341. PubMed ID: 35817438
[TBL] [Abstract][Full Text] [Related]
13. CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.
Li R; Xu X; Chen C; Wang Y; Gruzdev A; Zeldin DC; Wang DW
Am J Physiol Endocrinol Metab; 2015 Feb; 308(4):E270-82. PubMed ID: 25389363
[TBL] [Abstract][Full Text] [Related]
14. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme.
Lu J; Liu D; Zhou X; Chen A; Jiang Z; Ye X; Liu M; Wang X
Phytomedicine; 2018 Jan; 39():137-145. PubMed ID: 29433675
[TBL] [Abstract][Full Text] [Related]
15. Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes.
Aliwarga T; Evangelista EA; Sotoodehnia N; Lemaitre RN; Totah RA
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966295
[TBL] [Abstract][Full Text] [Related]
16. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
Shahabi P; Siest G; Visvikis-siest S
Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
[TBL] [Abstract][Full Text] [Related]
17. EETs and CYP2J2 inhibit TNF-α-induced apoptosis in pulmonary artery endothelial cells and TGF-β1-induced migration in pulmonary artery smooth muscle cells.
Feng W; Xu X; Zhao G; Li G; Liu T; Zhao J; Dong R; Wang DW; Tu L
Int J Mol Med; 2013 Sep; 32(3):685-93. PubMed ID: 23835530
[TBL] [Abstract][Full Text] [Related]
18. Cardiomyocyte-specific CYP2J2 and its therapeutic implications.
Valencia R; Bassiouni W; Darwesh AM; Bapuji R; Seubert JM
Expert Opin Drug Metab Toxicol; 2022; 18(7-8):423-439. PubMed ID: 35997132
[TBL] [Abstract][Full Text] [Related]
19. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.
Spiecker M; Darius H; Hankeln T; Soufi M; Sattler AM; Schaefer JR; Node K; Börgel J; Mügge A; Lindpaintner K; Huesing A; Maisch B; Zeldin DC; Liao JK
Circulation; 2004 Oct; 110(15):2132-6. PubMed ID: 15466638
[TBL] [Abstract][Full Text] [Related]
20. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders.
Shahabi P; Siest G; Meyer UA; Visvikis-Siest S
Pharmacol Ther; 2014 Nov; 144(2):134-61. PubMed ID: 24882266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
